Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma

Segatelli, Vanderlei; Oliveira, Ebe Christie de; Boin, I.F.S.F.; Ataíde, Elaine Cristina de; Escanhoela, C.A.F.

doi:10.1007/s12072-014-9525-9

Cited by 14 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, it was found that CD34 expression in HCC tumor tissue was a risk factor for recurrence. Furthermore, the morphology of VEGFR-2- and CD34-positive cells in HCC tumors reported in previous studies were consistent with those in the current study ( 39 – 41 ).…”

Section: Discussionsupporting

confidence: 92%

High expression of endothelial progenitor cell‑induced angiogenic markers is associated with bile acid levels in HCC

Chen

Wang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Endothelial progenitor cell (EPC)-induced angiogenesis activity is enhanced in hepatocellular carcinoma (HCC); however, the contributing factors remain unknown. The present study aimed to investigate the factors influencing the number of EPCs and circulating progenitor cells (CPCs), as well as the expression levels of vascular endothelial growth factor receptor 2 (VEGFR-2) and CD34, in patients with HCC. The expression levels of VEGFR-2 and CD34 were assessed in 72 HCC tumor and matched adjacent tissue microarrays by immunohistochemistry. The associations between VEGFR-2 or CD34 expression in tumors, clinicopathological characteristics and overall survival rates were analyzed. The number of EPCs and CPCs were analyzed in the peripheral blood of patients with HCC. In this study, high expression levels of VEGFR-2 and CD34 were detected in the tumor tissues of 41 (56.9%) and 44 (61.1%) patients, respectively. VEGFR-2 expression was significantly associated with tumor size (P<0.001), bile acid level (P=0.014) and α-fetoprotein level (P=0.011). However, CD34 expression was associated with tumor size (P=0.009), recrudescence (P<0.001) and bile acid (P= 0.009). Next, the expression levels of VEGFR-2 and CD34 in tumor and adjacent tissues were compared according to the bile acid level. VEGFR-2 and CD34 expression levels were both higher in the high bile acid group, whereas expression levels of the markers were higher in adjacent tissues compared with tumor tissues. Kaplan-Meier curve analysis identified that patients with low CD34 expression had a longer overall survival compared with patients with high CD34 expression (P=0.029). Multivariate analysis also indicated that both VEGFR-2 (P=0.020) and CD34 (P=0.035) were independent prognostic risk factors. Moreover, flow cytometry demonstrated that the number of EPCs and CPCs was negatively related with the bile acid levels in patients with HCC. In conclusion, in patients with HCC, bile acid promotes EPC-induced angiogenesis. Furthermore, EPCs and CPCs may be activated by bile acid in tumors but are more so in adjacent tissues.

show abstract

Section: Discussionsupporting

confidence: 92%

High expression of endothelial progenitor cell‑induced angiogenic markers is associated with bile acid levels in HCC

Chen

Wang

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…Angiogenesis is one of the best known stromal factors participating in tumor progression. [ 15 ] This has been extensively investigated in various tumors such as breast carcinoma,[ 16 ] hepatocellular carcinoma,[ 17 ] astrocytoma,[ 18 ] cervical carcinoma[ 19 ] and ovarian carcinoma. [ 20 ]…”

Section: Discussionmentioning

confidence: 99%

Quantitative evaluation of microvessel density using CD34 in clinical variants of ameloblastoma: An immunohistochemical study

Pereira

Dodal

Tamgadge

et al. 2016

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

Background:Odontogenic epithelium plays an important role in the histogenesis of odontogenic tumors of the jaws. Ameloblastomas, which arise from odontogenic epithelium, are considered benign with little tendency to metastasize. Tumors require an adequate supply of oxygen and a way to remove their waste products. This can be achieved by angiogenesis. In situ quantification of the microvessel density (MVD) is a usual method for assessing angiogenesis. Moreover, angiogenesis may differ in subtypes of ameloblastomas and could play a role in determining the pattern of tumor growth.Aim:The aim of the present study was to demonstrate the expression of cluster of differentiation (CD34) in variants of ameloblastomas and to correlate and compare their expression to the aggressive behavior.Materials and Methods:A retrospective cross-sectional study which included forty paraffin blocks was conducted after obtaining ethical committee clearance. Ten cases of pyogenic granuloma were used as a positive control and thirty cases were of solid multicystic ameloblastoma (SMA), unicystic ameloblastoma (UA) and desmoplastic ameloblastomas. Angiogenesis was assessed using CD34 antigen and was immunohistochemically localized. Statistical analysis was carried out for comparative analysis with the help of ANOVA test, Kolmogorov–Smirnov test and least significance difference test.Results:A significant correlation was obtained between the MVD of all the three variants, i.e., SMA, UA and desmoplastic ameloblastomas which was statistically significant (P < 0.05).Conclusion:Increased MVD in the three variants, i.e., SMA, UA and desmoplastic ameloblastoma seen in the present study could suggest that the angiogenesis has an important role in tumor progression and aggressiveness of ameloblastomas.

show abstract

“…Analysis of angiogenesis that is a proliferative factor for metastasis and tumor growth can be quantified by microvascular density (MVD). e MVD is evaluated by immunohistochemical assay using an endothelial marker (CD34) that is widely used for assessment of angiogenesis in HCC [35,36]. Endothelial cells can be derived from human peripheral CD34-positive cells and contribute to angiogenesis in adults [37].…”

Section: Discussionmentioning

confidence: 99%

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC

Hajighasemlou

Nikbakht

Pakzad

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed cancer and the second most common cause of cancer-related death worldwide. Sorafenib (Sora) is used as a targeted therapy for HCC treatment. Mesenchymal stem cells (MSCs) are applied as a new approach to fight malignancies. Drug resistance and side effects are the major concerns with Sora administration. The effect of using the combination of sorafenib and MSCs on tumor regression in xenograft HCC models was evaluated in this study. Methods and Materials. Human hepatocellular carcinoma cell lines (HepG2) were subcutaneously implanted into the flank of 18 nude mice. The animals were randomly divided into six groups (n = 3); each received Sora (oral), MSCs (IV injection), MSCs (local injection), Sora + MSCs (IV injection), Sora + MSCs (local injection), or no treatment (the control group). Six weeks after tumor implantation, the mice were scarified and tumoral tissues were resected in their entirety. Histopathological and immunohistochemical evaluations were used to measure tumor proliferation and angiogenesis. Apoptotic cells were quantified using the TUNEL assay. Results. No significant difference was found in the tumor grade among the treatment groups. Differentiation features of the tumoral cells were histopathologically insignificant in all the groups. Tumor necrosis was highest in the hpMSC (local) + Sora group. Tumor cell proliferation was reduced in hpMSC (local) + Sora-treated and hpMSC (IV) + Sora-treated mice compared with the other groups. Apoptotic-positive cells occupied a greater proportion in the Sora, hpMSC (IV) + Sora, and hpMSC (local) + Sora groups. Conclusion. A combination of chemotherapy and MSC can yield to more favorable results in the treatment of HCC.

show abstract

Evaluation and comparison of microvessel density using the markers CD34 and CD105 in regenerative nodules, dysplastic nodules and hepatocellular carcinoma

Abstract: MVD determined by CD34 and CD105 expression may be used as an additional parameter to distinguish benign from malignant liver nodules.

Cited by 14 publications

References 23 publications

High expression of endothelial progenitor cell‑induced angiogenic markers is associated with bile acid levels in HCC

High expression of endothelial progenitor cell‑induced angiogenic markers is associated with bile acid levels in HCC

Quantitative evaluation of microvessel density using CD34 in clinical variants of ameloblastoma: An immunohistochemical study

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC

Contact Info

Product

Resources

About